Takeda Pharmaceutical Company Limited (TYO:4502)
Japan flag Japan · Delayed Price · Currency is JPY
5,769.00
+67.00 (1.18%)
Aug 19, 2026, 3:30 PM JST

TYO:4502 Cash Flow Statement

Millions JPY. Fiscal year is Apr - Mar.
Fiscal Year
TTMFY 2026FY 2025FY 2024FY 2023FY 2022
Period Ending
Jun '26 Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Net Income
-163,436-152,390107,928144,067317,017230,059
Depreciation & Amortization
659,989678,583720,982728,002664,400583,151
Other Amortization
42,54442,54440,414---
Loss (Gain) From Sale of Assets
-3,883-15,197-5,703-1,780-6,797-7,174
Asset Writedown & Restructuring Costs
173,356145,716106,529150,01764,39454,515
Loss (Gain) From Sale of Investments
2501,006-60220,7573,991-11,195
Loss (Gain) on Equity Investments
1,1032,1773,986-6,4738,63015,367
Stock-Based Compensation
74,43472,77572,86770,87160,67243,374
Other Operating Activities
117,24066,31270,153-133,114-109,887116,403
Change in Accounts Receivable
-189,219-70,166-58,95915,10475,127127,294
Change in Inventory
-81,629-61,293-34,973-115,743-79,155-46,148
Change in Accounts Payable
1,720-3,150-7,118-9,895-84,804125,157
Change in Other Net Operating Assets
321,162334,51441,678-145,46963,568-107,698
Operating Cash Flow
953,6311,041,4311,057,182716,344977,1561,123,105
Operating Cash Flow Growth
-13.49%-1.49%47.58%-26.69%-13.00%11.10%
Capital Expenditures
-181,901-176,003-200,795-175,420-140,657-123,252
Sale of Property, Plant & Equipment
1,1656,454788,6069621,815
Cash Acquisitions
------49,672
Divestitures
14,49633,32520,55619,9597,95828,196
Sale (Purchase) of Intangibles
-257,200-234,930-147,046-305,310-493,032-62,785
Investment in Securities
-10,267-8,607-11,4071,25512,1038,580
Other Investing Activities
10,05610,620-28,446-12,9525,564-1,007
Investing Cash Flow
-423,651-369,141-367,060-463,862-607,102-198,125
Short-Term Debt Issued
--27,490277,00040,000-
Long-Term Debt Issued
-586,0601,024,460100,00075,000249,334
Total Debt Issued
402,505586,0601,051,950377,000115,000249,334
Short-Term Debt Repaid
--341,780----2
Long-Term Debt Repaid
--243,204-1,366,264-375,487-400,071-849,809
Total Debt Repaid
-412,738-584,984-1,366,264-375,487-400,071-849,811
Net Debt Issued (Repaid)
-10,2331,076-314,3141,513-285,071-600,477
Repurchase of Common Stock
-1,007-51,603-51,860-2,326-26,929-77,531
Common Dividends Paid
-316,737-311,901-302,498-287,188-279,416-283,665
Other Financing Activities
-134,291-134,392-82,753-66,415-117,732-108,592
Financing Cash Flow
-462,268-496,820-751,425-354,416-709,148-1,070,265
Foreign Exchange Rate Adjustments
43,26234,472-11,38526,20422,92928,758
Miscellaneous Cash Flow Adjustments
--11---
Net Cash Flow
110,974209,941-72,687-75,730-316,165-116,527
Free Cash Flow
771,730865,428856,387540,924836,499999,853
Free Cash Flow Growth
-15.29%1.06%58.32%-35.34%-16.34%11.13%
Free Cash Flow Margin
16.71%19.21%18.69%12.69%20.77%28.02%
Free Cash Flow Per Share
488.79549.46533.47342.28532.85633.95
Levered Free Cash Flow
541,444672,783735,617121,361480,297929,111
Unlevered Free Cash Flow
658,038765,360817,171193,481553,4051,005,631
Cash Interest Paid
120,264121,380112,984100,375108,555108,207
Cash Income Tax Paid
153,029172,562150,413202,039185,966140,423
Change in Working Capital
52,034199,905-59,372-256,003-25,26498,605